28 29 30 31 01 02 03
Economic Events
list Foreign Buying Japan Bonds (Yen)
list Foreign Buying Japan Stocks (Yen)
list Arvind Ltd | Bharat Forge | CESC | CESC
listNo IPO today

Orchid Pharma Q3 revenue at Rs3.22bn

India Infoline News Service/ Mumbai 17:33 , Feb 13, 2013

EBITDA of Rs 21.6 crore (US$ 3.9 mn) in Q3 FY13 versus Rs 129.0 crore (US$ 23.5 min) in Q3 FY12

Orchid Pharma registers turnover of Rs 322 crore in Q3 FY13
Financial highlights for Quarter ended December 31, 2012 (Q3 FY13)

Earnings on consolidated basis

Revenue of Rs 322 crore (US$ 58.5 mn) in Q3 FY13 versus Rs 496.8 crore (US$ 90.3 million) in Q3 FY12
EBITDA of Rs 21.6 crore (US$ 3.9 mn) in Q3 FY13 versus Rs 129.0 crore (US$ 23.5 million) in Q3 FY12
Loss before Tax of Rs 88.7 crore (US$ 16.1 mn) in Q3 FY13 compared to a profit before tax of Rs 41.1 crore (US$ 7.5 mn) during Q3 FY12
At the net level, the company registered a loss (after exceptional item loss of Rs 5.6 crore) of Rs 74.7 crore (US$ 13.6 mn) in Q3 FY13 compared to a loss of Rs 11.06 crore (US$ 2.0 million) during Q3 FY12

“The overall performance of the company continues to witness pressure due to the tight working capital levels and debt leverage. We are working on completing the transfer of our Penicillin & Carbapenem business to Hospira and will see a significantly deleveraged position from the deal proceeds leading to improved performance in the quarters to come”, said K Raghavendra Rao, Chairman & Managing Director, Orchid Chemicals & Pharmaceuticals Ltd.


Rate This Article Rate 1 Rate 2 Rate 3 Rate 4 Rate 5

Recent News Videos